Influence of medium-chain triglycerides (MCT) on ketone body synthesis at different glucose dosages in the human organism: A randomised controlled trial - C8arbo

Start Date03 Dec 2024

Sponsor / Collaborator

FH Canada

CTRI/2024/11/076163 / Not yet recruitingNot ApplicableIIT

Clinical study of two different doses of dextrose as a drug for prolotherapy treatment in patients of osteoarthritis knee pain - NIL

Start Date15 Nov 2024

Sponsor / Collaborator-

CTRI/2024/11/076304 / Not yet recruitingPhase 4IIT

Comparative study of 5% dextrose vs 18% dextrose prolotherapy in Myofascial pain syndrome

Start Date07 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Dextrose

100 Translational Medicine associated with Dextrose

100 Patents (Medical) associated with Dextrose

5,363

Literatures (Medical) associated with Dextrose

31 Dec 2024·Journal of Oral Microbiology

The effect of different sweeteners on the oral microbiome: a randomized clinical exploratory pilot study

Article

Author: Keijser, Bart J F ; van der Plas, Derek W K ; Zakis, Davis R ; Crielaard, Wim ; Volgenant, Catherine M C ; Brandt, Bernd W ; van der Waal, Suzette V ; Zaura, Egija

IntroductionThe aim of the study was to evaluate the modulating effects of five commonly used sweetener (glucose, inulin, isomaltulose, tagatose, trehalose) containing mouth rinses on the oral microbiome.MethodsA single-centre, double-blind, parallel randomized clinical trial was performed with healthy, 18-55-year-old volunteers (N = 65), who rinsed thrice-daily for two weeks with a 10% solution of one of the allocated sweeteners. Microbiota composition of supragingival dental plaque and the tongue dorsum coating was analysed by 16S RNA gene amplicon sequencing of the V4 hypervariable region (Illumina MiSeq). As secondary outcomes, dental plaque red fluorescence and salivary pH were measured.ResultsDental plaque microbiota changed significantly for two groups: inulin (F = 2.0239, p = 0.0006 PERMANOVA, Aitchison distance) and isomaltulose (F = 0.67, p = 0.0305). For the tongue microbiota, significant changes were observed for isomaltulose (F = 0.8382, p = 0.0452) and trehalose (F = 1.0119, p = 0.0098). In plaque, 13 species changed significantly for the inulin group, while for tongue coating, three species changed for the trehalose group (ALDEx2, p < 0.1). No significant changes were observed for the secondary outcomes.ConclusionThe effects on the oral microbiota were sweetener dependant with the most pronounced effect on plaque microbiota. Inulin exhibited the strongest microbial modulating potential of the sweeteners tested. Further full-scale clinical studies are required.

01 Dec 2024·International Journal of Biological Macromolecules

The effects of D-allulose on the gelatinization and gelling properties of wheat starch

Article

Author: Wang, Zhiqi ; Liu, Xinliang ; Lv, Jing ; Li, Ning ; Li, Xinyu ; Liu, Jidong ; Xie, Diandong

D-Allulose, with its low calorie content and sweetness comparable to sucrose, has gained significant attention from researchers as an ideal substitute for sucrose. Here, we investigated the effects of D-allulose on the physicochemical properties and texture of wheat starch. The gelatinization results showed that D-allulose (D-allulose: wheat starch = 1:1 w/w) increased the pasting temperature (56.4 to 65.2 °C) and transition enthalpy (7.9 to 9.0 J/g) of wheat starch systems, and the impact was significantly lower than that of other commonly used small-molecule sugars (sucrose, fructose, glucose). In addition, rheological, texture, and X-ray diffraction analyses confirmed that the addition of D-allulose improved the hardness, gumminess, and recrystallization of retrograded wheat starch gels. Microstructure analysis indicated that the addition of D-allulose enhanced the structural density of wheat starch system, thereby significantly slowing down the retrogradation of wheat starch. D-allulose exhibited unique properties, promoting the gelatinization of wheat starch and delaying its retrogradation. These results will help to promote the wide application of D-allulose in starchy foods with special physiological functions.

01 Dec 2024·Journal of Renal Care

The futility of post‐haemodialysis blood glucose levels: A retrospective cohort study

Article

Author: Xu, Qunyan ; Zhang, Jing ; Bennett, Paul ; Le Leu, Richard K.

AbstractBackgroundFrequent blood glucose tests are performed for people with diabetes receiving haemodialysis.ObjectivesTo determine the rate of out‐of‐range post‐haemodialysis blood glucose levels that are clinically acted upon, the intervention and outcome of each intervention, and the associations between post‐haemodialysis blood glucose levels and relevant clinical predictors.Design12‐month retrospective cohort medical record review in one Australian haemodialysis centre. Post‐haemodialysis blood glucose levels, prehaemodialysis blood glucose levels, time of treatment, diabetes medications, intradialytic fluid removal, dialysate dextrose concentration, clinical actions, interventions, and outcomes on out‐of‐range blood glucose levels were retrieved.Participants22 participants with a median time receiving dialysis 3.1 years (interquartile range 2.3−4.7).Measurements and ResultsThe proportion of out‐of‐range post‐haemodialysis blood glucose levels was 87.3% (95% confidence interval, 86.1%−88.5%). No out‐of‐range post‐haemodialysis blood glucose levels were clinically acted upon. Out‐of‐range post‐haemodialysis blood glucose levels were 4.6 times more likely if a higher dextrose bath was used (95% confidence interval: 3.3; 6.3. p < 0.001). The odds of the post‐haemodialysis blood glucose levels increased by each 1 mmol/L. Intradialytic fluid removal, dialysate dextrose concentration, sex, dialysis time, anti‐hyperglycaemic agents were also associated with out‐of‐range post‐haemodialysis blood glucose levels.ConclusionRoutine post‐haemodialysis blood glucose levels testing has limited clinical utility in care for people with diabetes receiving maintenance haemodialysis. Higher dextrose dialysate may require individual titration depending on prehaemodialysis blood glucose levels.

News (Medical) associated with Dextrose

22 Jun 2024

·www.globenewswire.com

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administrationThe results provide proof-of-concept for clinical efficacy of Aphaia’s oral glucose formulation, designed to restore endogenous nutrient-sensing pathways in the gastrointestinal tractThe study confirms that APHD-012 is well tolerated, with no serious adverse events observedAdditional results from a Phase 2 trial evaluating Aphaia’s formulation in individuals with obesity are expected in H2 2024 ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that its Phase 2 trial evaluating the company’s lead oral glucose formulation for prediabetes treatment met its primary endpoint. The trial showed a statistically significant improvement in glucose tolerance in individuals with a pathological Oral Glucose Tolerance Test (OGTT) after 6 weeks of APHD-012 administration compared to placebo, with a positive safety profile. "We are excited to demonstrate for the first time that the mechanism of action of APHD-012 translates into clinical efficacy,” said Steffen-Sebastian Bolz, M.D., Ph.D., chief scientific officer of Aphaia Pharma. “In addition to showcasing the potential of our oral glucose formulation to manage prediabetes progression, it also underscores its promise to deliver clinical benefits across various indications (e.g., diabetes, obesity, among others), given its mechanism of action in restoring natural hormone release patterns in the intestine. We look forward to analyzing the upcoming data from our ongoing Phase 2 trial of APHD-012 in individuals with obesity and associated metabolic diseases to determine the best strategic path forward.” Christian Sina, M.D., professor of Medicine at University of Luebeck, director of the Institute of Nutritional Medicine at UKSH, Germany, and principal investigator of the trial, added, “I am highly impressed with the data. It marks the first instance of a drug demonstrating effectiveness in OGTT with a positive safety profile, which is crucial for a medication aimed at disease prevention. Preventing diabetes is a priority in healthcare programs due to the significant health and economic burden associated with this disease. Despite efforts in diet and exercise, effective therapies to prevent or delay the onset of type 2 diabetes are currently lacking, posing a challenge for individuals who do not respond to lifestyle changes. I eagerly anticipate supporting the next steps for the program, which has the potential to open a new avenue for prediabetes treatment.” Key Trial Results include: In a group of healthy, prediabetic and diabetic patients, APHD-012 (6 weeks treatment) reduced OGTT blood glucose levels at 120 minutes post-challenge from 9.00.6 to 7.90.6 mmol/L (n=23, p=0.01); placebo treatment in the same patients had no significant effect (8.80.4 mmol/L versus 8.50.6 mmol/L; p=0.33)A subgroup analysis appears to show that APHD-012 has a larger effect size in prediabetic patients (8.70.4 to 6.80.5 mmol/L; n=12, p=0.003); placebo had no significant effect in this subgroup (8.60.4 versus 8.20.6 mmol/L; p=0.25).In a further analysis of prediabetic patients, APHD-012 treatment reduced OGTT area under the curve (AUC 0-120 minutes) from 126147 to 116336 min*mmol/L (p=0.004, n=12); the placebo treatment had no significant effect on AUC in this subgroup (125045 to 122553 min*mmol/L; p=0.47).In all diabetic patients included, APHD-012 treatment reduced OGTT blood glucose levels at 120 minutes post-challenge (from 13.20.7 to 11.60.5 mmol/L; n=5, p=0.0006); placebo was not effective in this group (11.40.5 versus 12.00.6 mmol/L; p=0.59).A total of 13 adverse events (AEs) were reported for 8 subjects (27%) during the 6 weeks of APHD-012 treatment, while 7 AEs were reported for 5 subjects (17%) taking placebo treatment; no serious AEs occurred during the course of the study. The Phase 2 trial (NCT05803772) (EudraCT 2022-003205-29) was a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study that evaluated the safety and efficacy of APHD-012 (12g dose of Aphaia’s oral glucose formulation) in approximately 30 adults with prediabetes, diabetes or healthy individuals in a cross-over design. Patients were randomized to receive a once daily dose of either APHD-012 or APHD-012P, a matching placebo, for six weeks, followed by a washout period of 4 weeks, and subsequent crossover to the other opposite treatment arm for another 6 weeks. The primary endpoint of the trial is APHD-012’s ability to improve glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration. The Oral Glucose Tolerance Test (OGTT) is a diagnostic test used to assess how well the body processes glucose by measuring blood glucose levels after consuming a glucose-rich drink. In individuals with diabetes and prediabetes, blood glucose levels are higher than normal due to their inability to metabolize glucose effectively. About PrediabetesPrediabetes is a serious health condition where blood sugar levels are elevated but not yet in the type 2 diabetes range. Prediabetes is becoming increasingly common and affects more than 10% of the population in Europe, the U.S. and Asia. Individuals with prediabetes are at increased risk of developing type 2 diabetes or associated complications, such as stroke or cardiovascular disease. While lifestyle changes can help prevent the progression from prediabetes to diabetes, there is a clear medical need for new therapeutic approaches to help control disease evolution before diabetes, cardiovascular disease and other metabolic disorders manifest. About Aphaia’s drug candidateAphaia’s lead drug candidate is a proprietary oral glucose formulation designed to be released at discrete parts of the small intestine to restore endogenous nutrient-sensing signaling pathways and stimulate the release of the broad spectrum of enteric hormones that control multiple homeostatic functions like appetite, hunger, satiety, glucose metabolism and energy expenditure. This includes glucagon-like-peptide 1 (GLP-1), peptide tyrosine-tyrosine (PYY), glicentin and oxyntomodulin (OXM) among others. About Aphaia PharmaAphaia Pharma is a clinical-stage biopharmaceutical company with headquarters in Switzerland, Canada and Puerto Rico. It harnesses proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead drug candidate, an oral glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns. Aphaia Investor ContactGünter JuchoChief Financial Officerjucho@aphaiapharma.com Media ContactMadelin HawtinLifeSci CommunicationsAphaiaPharma@lifescicomms.com

Phase 2Clinical Result

13 Jun 2024

·www.globenewswire.com

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity

Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulationTopline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 of the trial, respectively ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, June 13, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that it has completed enrollment in the second arm of its Phase 2 trial, which is evaluating the safety and efficacy of two separate doses of Aphaia’s formulation, or their respective placebos, twice per day to induce weight loss in individuals with obesity. The company had already completed enrollment in Part 1 of the trial, evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012), in April. "We are pleased to have completed enrollment for Arm 2 on schedule, allowing us to report topline data in Q4 2024, following Arm 1 data in Q3 2024,” said Steffen-Sebastian Bolz, M.D., Ph.D., chief scientific officer of Aphaia Pharma. “There is a large unmet need for treatment solutions for patients with obesity beyond hormone replacement therapy. We believe in the potential of our targeted oral glucose formulation to deliver long-term benefits for patients with minimal side effects, given its capacity to restore the endogenous release of the full spectrum of metabolically active hormones involved in satiety and glucose metabolism. Arm 2 of the trial will further allow us to refine the dosing regimen to optimize treatment response should we confirm an effect of circadian rhythm on treatment efficacy.” The Phase 2 trial (NCT05385978) is a randomized, double-blind, placebo-controlled, proof-of-concept study assessing the safety and efficacy of Aphaia’s oral glucose formulation in adults with obesity. It is comprised of two arms: Arm 1 includes two cohorts totaling 174 patients randomized to receive a once-daily dose of either APHD-012 (12g of Aphaia’s glucose formulation) or APH-012P, a matching placebo, prior to main daily meals for six (Cohort 1) or twelve months (Cohort 2). Arm 2 includes four cohorts with a total of 54 additional patients randomized to receive either 6g (APHD-006) or 8g (APHD-008) of Aphaia’s glucose formulation or their respective placebos twice per day. The primary endpoint of the trial is the change from baseline in percent weight compared to placebo. The study will also evaluate exploratory secondary endpoints, which are hallmarks of multiple metabolic diseases closely associated with obesity. About Aphaia’s drug candidateAphaia’s lead drug candidate is a proprietary oral glucose formulation designed to be released at discrete parts of the small intestine to restore endogenous nutrient-sensing signaling pathways and stimulate the release of the broad spectrum of enteric hormones that control multiple homeostatic functions like appetite, hunger, satiety, glucose metabolism and energy expenditure. This includes glucagon-like-peptide 1 (GLP-1), peptide tyrosine-tyrosine (PYY), glicentin and oxyntomodulin (OXM) among others. About Aphaia PharmaAphaia Pharma is a clinical-stage biopharmaceutical company with headquarters in Switzerland, Canada and Puerto Rico. It harnesses proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead drug candidate, an oral glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated in two Phase 2 trials, one for chronic weight management in individuals with obesity and the second to improve glucose tolerance in individuals with prediabetes. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns. Aphaia Investor ContactGünter JuchoChief Financial Officerjucho@aphaiapharma.com Media ContactMadelin HawtinLifeSci CommunicationsAphaiaPharma@lifescicomms.com

Phase 2

02 May 2024

·www.pharmaceutical-technology.com

Biotechs face upward battle with recruiting patients on obesity trials

Aphaia Pharma’s CEO Steffen Sebastian-Bolz discussed problems with obesity trial patient recruitment. Credit: Alexey Krukovsky via Getty Images, Following plans to add cohorts in an ongoing Phase II weight-loss study, Aphaia Pharma’s CSO Steffen-Sebastian Bolz says there are now rising challenges with the recruitment of patients in obesity trials . Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Go deeper with GlobalData Reports Obesity Market Size and Trend Report including Epidemiology, Diseas... Reports Gene Therapy Market Size, Share, Trends, Analysis and Forecast by R... Premium Insights The gold standard of business intelligence. Find out more Related Company Profiles Eli Lilly and Co View all Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check your inbox to download the Report. As per a 25 April press release, Aphaia Pharma has begun recruitment for four more cohorts in its weight-loss trial, investigating two formulations— 6g (APHD-006) and 8g (APHD-008)— of its therapy APDH-012. Bolz anticipates topline data in October. “It has become increasingly difficult to recruit patients because the [weight loss] space is absolutely crowded,” says Bolz. He explains that with the boom in obesity therapeutic development , pharmaceutical companies are running more and more clinical trials that extend past the usual Phase III programmes. He also highlights trials designed to evaluate cardiovascular risk as examples of this. Bolz says there is a “large discrepancy” between trial recruitment for large pharmaceutical companies and small biotech companies, as the financial incentives to participate in such trials can vary massively. Furthermore, obesity is a condition that has fewer official patient organisations than other medical conditions that can often be a useful resource for patient recruitment, he adds. Aphaia has just successfully completed recruitment for the first two cohorts of its weight loss study. In the last few years, the US Food and Drug Administration (FDA) has approved several therapies for weight loss and diabetes , including Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide). Thus far, Eli Lilly has published data from eight studies investigating tirzepatide for obesity and type 2 diabetes, but the company has plans to release data from several ongoing and upcoming studies in the next few years. See Also: Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1 ePRO vs eCOA: Understanding the nuances in clinical trials Bolz says that Aphaia Pharma has not had trouble with recruitment due to its drug’s unique mechanism of action, which leads to very few side effects. APHD-012 gives a targeted release of glucose that restores endogenous nutrient-sensing signalling pathways and triggers the release of enteric hormones related to the systems for appetite, hunger, satiety, glucose metabolism, and energy expenditure. This includes hormones such as glucagon-like peptide 1 (GLP-1), peptide tyrosine-tyrosine (PYY), glicentin and oxyntomodulin (OXM). Furthermore, Bolz highlighted the company’s efforts to form a tight relationship with its CRO partners and medical centres, enabling Aphaia to reach out to patients through its partners’ networks. He adds that through this method, centres can also forward essential drug information to the patients, increasing compliance. The oral therapy is currently being assessed in a Phase II weight-loss trial (NCT05385978) and a Phase II prevention trial for prediabetic patients (NCT05803772). The Swiss biotech is developing and investigating the therapy in the US, Canada, Puerto Rico, Germany, and the country of Georgia. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check your inbox to download the Report.

Phase 2Phase 3

100 Deals associated with Dextrose

External Link

KEGG	Wiki	ATC	Drug Bank
D02325	Dextrose	-	DB09341

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Water-Electrolyte Imbalance	US	Baxter Healthcare Corp.	25 Jan 1971

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	US	Aphaia Pharma AG	01 Apr 2023
Prediabetic State	Phase 2	US	Aphaia Pharma AG	01 Apr 2023
Obesity	Phase 2	DE	Aphaia Pharma AG	01 Jul 2022
Obesity	Phase 2	PR	Aphaia Pharma AG	01 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01369147 (CTgov)	Phase 2	Critical Illness	12	Enteral feeding+Propofol+Clevidipine+Dextrose-containing IV Fluids (Parenteral Nutrition Energy Dose at 0.6 x Measured REE)	rcjatdufxx(sckhqefgvx) = xjrgklmdbv xyxvbgqymv (pygmyaobsg, pxmkavssxm - terawkppmm) View more	-	10 Jun 2022
				Enteral feeding+Propofol+Clevidipine+Dextrose-containing IV Fluids (Parenteral Nutrition Energy Dose at 1.0 x Measured REE)	rcjatdufxx(sckhqefgvx) = jncuvxfmrv xyxvbgqymv (pygmyaobsg, wuwzwgtgjg - dfitpjmtes) View more
ADA2021	Not Applicable	Hypoglycemia	10	Glucose	kgwruefgic(kjmrtevmwc) = kodxhoayfb yfciggwkhc (xnpifefhyf ) View more	-	01 Jun 2021
ADA2020	Not Applicable	Diabetes Mellitus, Type 2	12	Tofogliflozin	(odzcdvqqtk) = rpgxfechcl weetjmhybb (qypfnecvlj )	-	01 Jun 2020
				Tofogliflozin (No administration of drugs)	(odzcdvqqtk) = mwjioppdda weetjmhybb (qypfnecvlj )
ASN2019	Not Applicable	Hyperkalemia	142	Intravenous Insulin and Dextrose 50%	mqutoughpx(bhozzzltog) = hlqjzladzz ciipcltdzp (jowliturqf, 1.67 - 16.0) View more	Positive	05 Nov 2019
NCT03095651 (5160-002 \| MK-5160-002, CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Diabetes Mellitus, Insulin-Dependent, 2	33	Placebo to Glargine+MK-5160 16 nmol/kg+Dextrose (T1DM MK-5160 16 Nmol/kg)	mzdkirqpcp(onlaypkdae) = lxtvbzmrje bpxifhtaov (srbikhgzgw, yejhgyqoqq - ynxbsnoytj) View more	-	01 Apr 2019
				Placebo to Glargine+MK-5160 32 nmol/kg+Dextrose (T1DM MK-5160 32 Nmol/kg)	mzdkirqpcp(onlaypkdae) = fhdliwggoh bpxifhtaov (srbikhgzgw, gkfatwminc - ihxuivwzjq) View more
NCT05548738 (Pubmed \| J Altern Complement Med)	Phase 2/3	Leg/buttock pain	32	Caudal Epidural D5W	(jpkoaydrhg) = yhoxqyqyau xmomoizcyr (txndkmctfv )	Positive	01 Dec 2018
NCT00578669 (CTgov)	Phase 3	Depressive Disorder, Major \| Nicotine Dependence	206	Fluoxetine (Sequential Fluoxetine)	zimjcbirck(ueartzqxtz) = xkgesoegkr xalkymijrd (ymxzrtzmoa, rfypwhllrw - pxmablgjjo) View more	-	16 Oct 2018
				nicotine+placebo+Dextrose (Sequential Placebo)	zimjcbirck(ueartzqxtz) = lsfzpmktqd xalkymijrd (ymxzrtzmoa, fcmeryvyep - gvjumohbkb) View more
Pubmed	Not Applicable	Low Back Pain	35	5% Dextrose	vshqmitfxj(pogsaxpbgs) = goexstqmbn cfayfywdud (niiwbddsig ) View more	-	06 Dec 2016
				0.9% Saline	vshqmitfxj(pogsaxpbgs) = tlopvcustb cfayfywdud (niiwbddsig ) View more
ESPE2014	Not Applicable	Diabetes Mellitus	-	Coated Pellets With Controlled Glucose Release	awebyokbxp(zkkjsrolin) = exsjylpoyv ofdzcadmrj (xuseyvqifx ) View more	Positive	18 Sep 2014
ARVO2014	Not Applicable	-	-	glucose	(ifxpghsjin) = kdkaronjaf pjzdmjaypz (jrcwzvpecj, 832.5)	-	01 Apr 2014
				glucose	(ifxpghsjin) = vpswdlitcc pjzdmjaypz (jrcwzvpecj, 432.05)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis